<DOC>
	<DOCNO>NCT00982124</DOCNO>
	<brief_summary>The investigator currently finish conduct international multi-center trial compare efficacy safety pamidronate zoledronate treatment moderate severe form Osteogenesis Imperfecta ( OI ) . This trial include child one year age . The aim current study extend observation currently finish study infant 1 year age . Moreover , possible administer zoledronate single short infusion instead three-day cycle Pamidronate , therefore decrease patient family burden short stays hospital .</brief_summary>
	<brief_title>An Efficacy Safety Trial Intravenous Zoledronic Acid Infants Less Than One Year Age , With Severe Osteogenesis Imperfecta</brief_title>
	<detailed_description />
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Children , male female 2 week &lt; 12 month age , least 38 week gestational age . Any child phenotypic OI type II , III IV . Any child classify OI type I , VVIII least two previous fracture long bone , vertebral compression fracture , low bone mineral density . No previous treatment bisphosphonates . Negative urine protein measure dipstick . One repeat assessment urine protein allow . Blood oxygen saturation le 90 % room air . Serum creatinine level great 56 Âµmol/L . Any clinically significant clinical laboratory abnormality screen . Treatment investigational drug within past 30 day . Patients unlikely able complete study comply visit schedule . Any disease plan therapy interfere procedure data collection trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Osteogenesis Imperfecta</keyword>
	<keyword>Infants moderate severe Osteogenesis Imperfecta</keyword>
</DOC>